Peer-reviewed work by BioAnalix founders, and selected reading from other groups that frames the problems our programmes address.
Protein and enzyme stability engineering
Pezeshgi Modarres H, Mofrad MRK, Sanati-Nezhad A. ProtDataTherm: A database for thermostability analysis and engineering of proteins. PLOS ONE, 2018;13(1):e0191222.
doi:10.1371/journal.pone.0191222
A systematic analysis of the sequence and structural features that separate thermostable proteins from their mesophilic counterparts, assembled into a resource for stability engineering. This is the direct scientific ancestor of our stability platform.
Pezeshgi Modarres H, Dorokhov BD, Popov VO, Ravin NV, Skryabin KG, Dal Peraro M. Understanding and Engineering Thermostability in DNA Ligase from Thermococcus sp. 1519. Biochemistry, 2015;54(19):3076–3085.
doi:10.1021/bi501227b
Computational and experimental dissection of what makes one enzyme hold its fold at temperatures that destroy another — and how targeted substitutions shift that boundary.
Biosensing and diagnostics
Sajjadi SM, Abooalizadeh Z, Banoei MM, Babamiri B, Kolahchi AR, Mohammadi MH, Sanati-Nezhad A. Smart materials for biosensing of infectious diseases: mechanisms, materials, platforms, and translational opportunities. Biosensors and Bioelectronics: X, 2026;100843.
doi:10.1016/j.biosx.2026.100843
Organ-on-chip and drug screening
Rezaei Kolahchi A, Khadem Mohtaram N, Pezeshgi Modarres H, Mohammadi MH, Geraili A, Jafari P, Akbari M, Sanati-Nezhad A. Microfluidic-based multi-organ platforms for drug discovery. Micromachines, 2016;7(9):162.
doi:10.3390/mi7090162
Design principles for interconnected organ models, and the problems that appear once organs are modelled together: scaling, cell selection, shared medium, and study design for drugs acting on multiple targets. The groundwork for PWS-on-Chip.
Valente KP, Khetani S, Kolahchi AR, Sanati-Nezhad A, Suleman A, Akbari M. Microfluidic technologies for anticancer drug studies. Drug Discovery Today, 2017;22(11):1654–1670.
PubMed 28684326
Rahmanian M, Seyfoori A, Ghasemi M, Shamsi M, Rezaei Kolahchi A, Pezeshgi Modarres H, Sanati-Nezhad A, Majidzadeh-A K. In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies. Journal of Controlled Release, 2021;334:164–177.
doi:10.1016/j.jconrel.2021.04.024
Selected reading from other groups
Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics, 2022;23:467–491.
doi:10.1038/s41576-022-00466-9
Sontheimer-Phelps A, Hassell BA, Ingber DE. Modelling cancer in microfluidic human organs-on-chips. Nature Reviews Cancer, 2019;19:65–81.
doi:10.1038/s41568-018-0104-6
These are not our work. They are included because they set out, better than we could, why organ-level models matter for drug development — the premise the PWS-on-Chip programme is built on.
